CKD Bio 과거 수익 실적
과거 기준 확인 0/6
CKD Bio's earnings have been declining at an average annual rate of -121.1%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 3.6% per year.
주요 정보
-121.1%
수익 성장률
-121.1%
EPS 성장률
Pharmaceuticals 산업 성장 | 11.3% |
매출 성장률 | 3.6% |
자기자본 수익률 | -17.6% |
순이익 | -14.5% |
최근 수익 업데이트 | 30 Sep 2023 |
최근 과거 실적 업데이트
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30수익 및 비용 분석
CKD Bio 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 23 | 159,935 | -23,130 | 15,057 | 16,277 |
30 Jun 23 | 155,183 | -20,233 | 15,377 | 15,272 |
31 Mar 23 | 152,876 | -18,403 | 15,251 | 15,341 |
31 Dec 22 | 156,042 | -16,703 | 15,513 | 15,432 |
30 Sep 22 | 154,395 | -10,462 | 13,971 | 13,939 |
30 Jun 22 | 154,759 | -11,222 | 13,750 | 12,777 |
31 Mar 22 | 155,569 | -5,821 | 13,246 | 11,940 |
31 Dec 21 | 142,238 | -6,577 | 12,585 | 11,516 |
30 Sep 21 | 135,760 | -6,730 | 12,105 | 10,878 |
30 Jun 21 | 130,483 | -1,111 | 11,355 | 10,667 |
31 Mar 21 | 127,741 | 1,771 | 11,109 | 10,114 |
31 Dec 20 | 124,600 | 6,207 | 10,538 | 9,118 |
30 Sep 20 | 135,773 | 10,664 | 9,873 | 9,900 |
30 Jun 20 | 138,042 | 12,633 | 9,852 | 10,455 |
31 Mar 20 | 136,265 | 12,446 | 9,718 | 10,584 |
31 Dec 19 | 137,184 | 12,265 | 10,057 | 10,704 |
30 Sep 19 | 129,529 | 10,563 | 9,913 | 9,919 |
30 Jun 19 | 127,134 | 9,605 | 9,347 | 9,074 |
31 Dec 18 | 124,510 | 7,956 | 8,530 | 7,881 |
양질의 수익: A063160 is currently unprofitable.
이익 마진 증가: A063160 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: Insufficient data to determine if A063160's year-on-year earnings growth rate was positive over the past 5 years.
성장 가속화: Unable to compare A063160's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: A063160 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
자기자본 수익률
높은 ROE: A063160 has a negative Return on Equity (-17.58%), as it is currently unprofitable.